Abstract
AbstractCognitive impairment is an important nonmotor symptom in Parkinson's disease (PD). In recent years, much research has focused on cholinergic dysfunction as a principal cause of early cognitive decline in PD. Cholinergic dysfunction is common and produces characteristic impairments in multiple cognitive domains; furthermore, it is associated with future dementia in PD. Recently, it has become possible to measure the volume of the human cholinergic nucleus, and this technique has been increasingly applied in PD research. Here, we review the current state of knowledge on cognitive dysfunction and neuroimaging studies, with particular focus on atrophy of the cholinergic nucleus in PD.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
